Background: A Decade of Long-Term Survival Data
Over more than a decade, the KEYNOTE studies have shaped first-line treatment standards for advanced NSCLC. A pooled analysis with up to 10 years of follow-up, presented at the 2025 European Society for Medical Oncology (ESMO) Congress (Abstract 3208P), suggests that pembrolizumab monotherapy may deliver durable survival in a meaningful proportion of patients whose tumors express programmed death-ligand 1 (PD-L1) and lack targetable driver alterations [1].
KEYNOTE-001: 10-year overall survival (OS) rate of 19.3%.
KEYNOTE-024: 8-year OS rate of 24.3%.
KEYNOTE-042: 8-year OS rate of 16.6%.
Where the chemotherapy era rarely delivered 5-year survival above 5%, the immunotherapy era has brought 10-year survival close to 20% in selected populations. This feature collects the views of three experts - Jie Hu, Min Fan, and Anwen Xiong - on what these long-term findings may mean in specific clinical contexts.
Expert Profile
Jie Hu
·MD, PhD, Chief Physician
·Deputy Chief, Department of Pulmonary and Critical Care Medicine
·Shanghai Geriatric Medical Center (Minhang Branch, Zhongshan Hospital, Fudan University)
·Focus: precision treatment of elderly patients with advanced NSCLC.
Min Fan
·MD, Chief Physician;
·Deputy Chief, Radiotherapy Center, Fudan University Shanghai Cancer Center;
·Deputy Director, Fudan University Shanghai Chest Cancer Institute.
·Focus: re-evaluation of the role of radiotherapy in the immunotherapy era.
Wen’an Xiong
·MD, Associate Chief Physician and Associate Professor,
·Department of Oncology, Shanghai East Hospital, Tongji University.
·Focus: immunotherapy as the backbone of long-term survival and emerging combination strategies.
Older Adults With Advanced NSCLC - Long-Term Survival May Also Be Within Reach
Expert Jie Hu, MD, PhD
A pooled analysis of KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 reported a hazard ratio (HR) of 0.76 for overall survival (OS) favoring pembrolizumab over chemotherapy in patients aged 75 years and older with a PD-L1 tumor proportion score (TPS) of 1% or higher; in patients with PD-L1 TPS of 50% or higher, the corresponding HR was 0.40 [2].
Combination regimens may also be active across age groups.
In subgroup analyses, the HR for OS with pembrolizumab plus chemotherapy versus chemotherapy alone was 0.64 in patients aged 65 years and older in KEYNOTE-189 (non-squamous NSCLC) and 0.74 in patients aged 65 years and older in KEYNOTE-407 (squamous NSCLC) [3, 4]. These observations, drawn from subgroup analyses rather than pre-specified analyses, suggest that immunotherapy-based combinations may be feasible in older patients selected by fitness rather than chronological age.
Two shifts in clinical practice were noted:
· Chronological age, alone, is no longer a contraindication to immune checkpoint inhibitor therapy.
· Tolerability of immunotherapy is increasingly viewed as an advantage rather than a concern in appropriately selected older patients.
Guidance from the 2025 Chinese Expert Consensus
The Chinese Expert Consensus on Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer in the Elderly (2025 Edition), issued by the National Center for Geriatric Medicine, the Lung Cancer Committee of the Beijing Cancer Society, and the Editorial Board of the Chinese Journal of Geriatrics, provides the following practical framework [5]:
Aged 65-74 years and deemed fit: immune checkpoint inhibitor (ICI) plus platinum-based doublet chemotherapy is preferred; ICI plus single-agent chemotherapy is an option for those who are less fit.
Aged 75 years and older, PD-L1 TPS 50% or higher: pembrolizumab monotherapy is recommended.
Aged 75 years and older, PD-L1 TPS below 50%: ICI plus single-agent chemotherapy is recommended for those who are fit; ICI monotherapy is recommended for those who are not.
Re-examining the Role of Radiotherapy in the Long-Term Survival Era
Expert Min Fan, MD
The 10-year pooled analysis of KEYNOTE-001, KEYNOTE-024, and KEYNOTE-042, presented at the 2025 ESMO Congress, reported the following long-term OS rates for patients with PD-L1 TPS of 50% or higher [1]:
· KEYNOTE-001: 10-year OS rate of 19.3%.
· KEYNOTE-024: 8-year OS rate of 24.3%.
· KEYNOTE-042: 8-year OS rate of 16.6%.
Mechanistic rationale for combining radiotherapy with immunotherapy
Two mechanisms cited in support of the combination include:
1. Antigen release: Radiation-induced tumor cell death may release tumor-associated antigens, potentially priming or "sensitizing" the immune system.
2. Microenvironment remodeling: Radiation may reshape the tumor microenvironment, improving conditions for lymphocyte infiltration and supporting the conversion of so-called "cold" tumors into "hot" tumors.
Clinical scenarios require differentiation
Oligometastatic disease (limited metastases at initial diagnosis): the evidence base supporting a benefit from radiotherapy is relatively robust.
Oligo-residual or oligo-progressive disease (a small number of lesions that fail to respond or progress after systemic therapy): the evidence base remains under investigation, with prospective trials still maturing.
Long-Term Survival Enters Clinical Practice - and Reach Expands
Expert Anwen Xiong, MD, PhD
In KEYNOTE-024, first-line pembrolizumab monotherapy in PD-L1-high patients was associated with a 5-year OS rate of 31.9% [6]. In KEYNOTE-042, the corresponding 5-year OS rate in PD-L1-high patients was 21.9% [7].
Ten-year data suggest durability
In the 10-year pooled analysis of KEYNOTE-001/024/042, the 8-year and 10-year OS rates for PD-L1-high patients receiving first-line pembrolizumab monotherapy remained close to 20% [1]. KEYNOTE-189 (non-squamous) and KEYNOTE-407 (squamous) have shown that pembrolizumab plus chemotherapy is associated with survival gains across patient subgroups [3, 4].
New combinations are emerging
The randomized phase 3 OptiTROP-Lung05 study, reported at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 8506), evaluated the trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) plus pembrolizumab versus pembrolizumab alone as first-line treatment for PD-L1-positive advanced NSCLC. According to the meeting abstract, the combination showed greater progression-free survival (PFS) benefit than pembrolizumab monotherapy [8]. As of the meeting presentation, the data have not yet been peer-reviewed; longer follow-up and full publication are awaited.
Conclusion
The decade-spanning follow-up of the KEYNOTE trials has accumulated evidence that immunotherapy may deliver long-term survival in a meaningful proportion of patients with advanced NSCLC. Whether this potential translates into practice-changing decisions will continue to be defined through ongoing research, guideline updates, and real-world experience in diverse patient populations.
References
[1] Garon EB, et al. 10-year outcomes from clinical trials of pembrolizumab (pembro) monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC). 2025 ESMO. Abstract 3208P.
[2] Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042. Lung Cancer. 2019;135:188-195.
[3] Gadgeel S, Rodriguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505-1517.
[4] Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040-2051.
[5] National Center for Geriatric Medicine, Lung Cancer Committee of Beijing Cancer Society, Editorial Board of Chinese Journal of Geriatrics. Chinese Expert Consensus on Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer in the Elderly (2025 Edition). Chin J Geriatr. 2025;44(6):677-699.
[6] Reck M, Rodriguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >=50%. J Clin Oncol. 2021;39(21):2339-2349.
[7] de Castro G Jr, Kudaba I, Wu YL, et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score >=1% in the KEYNOTE-042 study. J Clin Oncol. 2023;41(11):1986-1991.
[8] Zhou C, et al. Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC): results from the randomized phase 3 OptiTROP-Lung05 study. 2026 ASCO. Abstract 8506.